Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $200.4 million versus the consensus estimate of $202.39 million.

GUIDANCE:

Myriad Genetics sees FY2026 revenue of $80.6-0.88 billion, versus the consensus of $1.53 billion.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.